Want to see AVIR full AI Analyst Report?
AVIR Stock Chart & Stats
$4.73
-$0.02(-0.42%)
At close: 4:00 PM EDT
$4.73
-$0.02(-0.42%)
Day’s Range― - ―
52-Week Range$2.78 - $6.45
Previous Close$4.82
Volume381.47K
Average Volume (3M)331.21K
Market Cap
$376.13M
Enterprise Value$170.71
Total Cash (Recent Filing)$256.01M
Total Debt (Recent Filing)$634.00K
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 06, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.11
Shares Outstanding80,027,100
10 Day Avg. Volume266,515
30 Day Avg. Volume331,208
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)1.06
Price to Sales (P/S)0.00
P/FCF Ratio-2.20
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside26.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.92
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthAtea's extremely low leverage provides durable financial flexibility to fund R&D and clinical programs without immediate debt servicing pressure. This reduces bankruptcy risk, supports strategic options (partnering, staged spend) and improves survival odds through long development timelines.
Phase 3 Execution ProgressCompleted, well-powered Phase 3 enrollment materially lowers execution risk and shortens time to pivotal readout. Durable benefit: successful trial operations increase probability of regulatory submission, partner interest, and eventual commercialization if efficacy/safety readouts are positive.
Commercial & Manufacturing ReadinessConcentrated prescriber base and demonstrated prescriber intent combined with manufacturing readiness create a durable go‑to‑market advantage. This supports a capital‑efficient commercial roll‑out, faster uptake upon approval, and lower supply chain execution risk versus peers starting from scratch.
Bears Say
No Revenue And Large Ongoing LossesZero recurring revenue and persistent large cash burn make the business model dependent on external financing or successful clinical outcomes. Over the medium term this elevates dilution and execution risk, and constrains strategic optionality if trial setbacks or slower adoption occur.
Limited Cash Runway Beyond 2027While current cash funds near‑term milestones, projected runway only through 2027 implies likely fundraising before commercialization or extended development. Recurring financing needs can dilute shareholders, distract management with capital raises, and add execution risk if market conditions tighten.
Regulatory Complexity Across TrialsDifferent primary analysis populations across regions complicate regulatory strategy, may require additional analyses, and risk staggered approvals or label differences. This structural complexity can delay launches, increase regulatory costs, and create uncertainty for global commercialization planning.
Atea Pharmaceuticals News
AVIR FAQ
What was Atea Pharmaceuticals’s price range in the past 12 months?
Atea Pharmaceuticals lowest stock price was $2.78 and its highest was $6.45 in the past 12 months.
What is Atea Pharmaceuticals’s market cap?
Atea Pharmaceuticals’s market cap is $376.13M.
When is Atea Pharmaceuticals’s upcoming earnings report date?
Atea Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 2 days.
How were Atea Pharmaceuticals’s earnings last quarter?
Atea Pharmaceuticals released its earnings results on May 12, 2026. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.555 by -$0.015.
Is Atea Pharmaceuticals overvalued?
According to Wall Street analysts Atea Pharmaceuticals’s price is currently Undervalued.
Does Atea Pharmaceuticals pay dividends?
Atea Pharmaceuticals does not currently pay dividends.
What is Atea Pharmaceuticals’s EPS estimate?
Atea Pharmaceuticals’s EPS estimate is -0.56.
How many shares outstanding does Atea Pharmaceuticals have?
Atea Pharmaceuticals has 80,027,100 shares outstanding.
What happened to Atea Pharmaceuticals’s price movement after its last earnings report?
Atea Pharmaceuticals reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.555. Following the earnings report the stock price went down -16.909%.
Which hedge fund is a major shareholder of Atea Pharmaceuticals?
Currently, no hedge funds are holding shares in AVIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atea Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (26.85% Upside)
$6.00 (26.85% Upside)
Blogger Sentiment
Bullish
AVIR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 12.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-39.30%
Trailing 12-Months
Company Description
Atea Pharmaceuticals
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
AVIR Company Deck
AVIR Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a largely positive outlook driven by strong operational progress: completed enrollment for the U.S. Phase 3 (C‑BEYOND), near‑complete enrollment ex‑U.S. (C‑FORWARD), a well‑powered trial design (90% power, 5% non‑inferiority), an advancing HEV program (CTA enabling studies done, FIH mid‑year), clear prescriber interest, manufacturing readiness, and $256M in cash with runway through 2027. Key risks include a limited cash runway beyond 2027, higher R&D spend, regulatory complexity (different primary analysis populations for FDA vs EMA), payer and market access uncertainties, and clinical/regulatory risk for the novel HEV program. On balance, operational milestones and program momentum outweigh the noted risks.View all AVIR earnings summariesAVIR Stock 12 Month Forecast
Average Price Target
$6.00
▲(26.85% Upside)
Technical Analysis
Ownership Overview
11.29% Insiders
16.76% Mutual Funds
0.78% Other Institutional Investors
59.81% Public Companies and
Individual Investors